Alli is an oral medicine for adults who are working toward weight reduction. Its active ingredient, orlistat, is a lipase inhibitor that reduces the amount of dietary fat absorbed in the gut.
Alli is an oral weight-management medicine containing orlistat. It is intended for adults working toward weight reduction through lower-fat eating and regular physical activity. Orlistat acts in the gut, reducing the amount of dietary fat absorbed from a meal.
Alli capsules contain orlistat, a lipase inhibitor. Lipases are digestive enzymes that split dietary fat into absorbable components. By blocking part of this enzyme activity in the stomach and small intestine, orlistat leaves some meal fat unabsorbed and eliminates it in the stool [1].
Alli does not suppress appetite or stimulate metabolism. Its benefit depends on the fat content of meals. A lower-fat, calorie-controlled eating pattern makes treatment more comfortable and more useful.
Take one Alli capsule with each main meal that contains fat. The capsule may be taken shortly before, during, or up to one hour after that meal. If a meal is skipped or contains no fat, skip the capsule for that meal.
The approved use pattern for orlistat links each dose to food rather than to a fixed clock time. The European Medicines Agency describes this meal-linked approach for orlistat treatment and highlights the importance of nutritional planning during use [2].
Orlistat works locally in the digestive tract. It binds to gastric and pancreatic lipases, reducing the digestion and absorption of dietary triglycerides. The medication has minimal systemic absorption, so it does not act directly on the brain’s hunger centres.
The mechanism creates a clear trade-off. Alli can support weight loss without stimulant effects such as palpitations or insomnia, yet digestive effects are common when meals are rich in fat. Weight reduction still relies on a sustained calorie deficit.
Fat-soluble vitamins need attention. Vitamins A, D, E, and K may be absorbed less efficiently during treatment because their uptake depends partly on dietary fat.
Alli is intended for adults working toward weight reduction alongside lower-fat eating and regular physical activity. Its active ingredient, orlistat, reduces the amount of dietary fat absorbed from meals in the gut. Use each capsule with a main meal that contains fat, following the directions stated on the pack.
Weight management medicines differ most in where they act. Alli acts on dietary fat in the gut, while other options may influence appetite, blood glucose regulation, or nutrient absorption.
| Approach | Main action | Practical limitation |
|---|---|---|
| Orlistat | Reduces absorption of dietary fat in the intestine | Digestive effects rise after fatty meals |
| GLP-1 receptor agonists | Increase fullness and slow stomach emptying | Usually require prescription assessment and may cause nausea |
| Appetite-focused medicines | Act on brain pathways that regulate hunger | May be unsuitable with some cardiovascular, psychiatric, or seizure-related conditions |
NICE guidance published in 2025 places medication within a broader obesity-management plan that includes nutrition, activity, sleep, and follow-up rather than treating a capsule as a stand-alone solution [3]. Alli is most suited to people who prefer a non-stimulant option and can maintain consistent control of meal fat.
This is NOT for you if you have chronic malabsorption syndrome or cholestasis, a condition where bile flow from the liver is blocked. It should also be avoided if you have previously had an allergic reaction to orlistat or any capsule component.
Avoid Alli if you have a condition that prevents normal absorption of food or bile flow from the liver, or if you have ever had an allergic reaction to orlistat or one of its capsule ingredients.
Speak with a clinician before use if you are pregnant or breastfeeding, have kidney disease, diabetes, an eating disorder, thyroid disease, or take medicines such as levothyroxine, ciclosporin, warfarin, anti-epileptic medicines, amiodarone, or antiretroviral treatment.
Digestive effects are the main limitation of Alli. They occur because unabsorbed fat remains in the bowel. Common effects include oily or fatty stools, gas with oily discharge, increased bowel movements, loose stools, abdominal discomfort, and a need to reach a toilet quickly.
These effects are usually most noticeable early in treatment or after meals high in fat. They often improve when fat portions become smaller and are spread through the day.
More serious reactions are uncommon but need prompt medical assessment. Seek urgent care for facial swelling, breathing difficulty, widespread rash, severe or persistent abdominal pain, yellowing of the skin or eyes, dark urine, or a major change in urine output. Rare cases of severe liver injury and kidney problems linked to oxalate deposits have been reported with orlistat [5].
Several patterns make Alli less comfortable or less useful:
One common misconception is that Alli blocks all fat from food. It does not. Some fat is still absorbed, and calorie intake still matters.
Clinicians usually frame Alli as a behaviour-linked medicine. It provides immediate feedback: high-fat meals are more likely to cause bowel effects, while planned meals tend to be better tolerated. This can help some people recognise portion sizes and hidden sources of fat.
WHO’s 2024 obesity guidance describes excess weight as a chronic, relapsing health issue influenced by biology, environment, diet, activity, sleep, medicines, and mental health [4]. A capsule cannot remove all of these influences. Progress is usually steadier when the plan also includes realistic meals, movement that fits daily life, and adequate sleep.
A useful expectation is gradual change. Rapid weight swings often reflect fluid shifts or overly restrictive eating rather than sustainable fat loss.
No. Alli does not directly reduce hunger or alter appetite-regulating brain signals. It works by reducing the absorption of some dietary fat in the digestive tract. The FDA’s orlistat information distinguishes this intestinal mechanism from centrally acting weight-management medicines; its 2024 prescribing information also links use to a reduced-calorie, low-fat diet. Hunger can still occur, so meals need enough protein, fibre, and volume from vegetables.
Weight change is usually gradual because the medicine affects only part of dietary fat absorption. NHS-style obesity care principles reflected in NICE’s 2025 guidance focus on sustained dietary and activity changes over weeks and months rather than day-to-day scale fluctuations. Weighing once weekly under similar conditions gives a clearer trend. A sudden large change over a few days is more likely to reflect fluid, salt intake, or bowel contents than body-fat change.
Alcohol does not have a direct major interaction with orlistat in standard medicine references. It can still add calories and may reduce adherence to a calorie-controlled eating plan. The EMA’s product information for orlistat, reviewed in 2023, focuses on meal fat content and interaction management rather than alcohol avoidance. Choosing lower-calorie drinks and avoiding fried or rich food alongside alcohol can reduce digestive problems.
Oily stools occur when undigested dietary fat passes through the bowel. This is a predictable effect of lipase inhibition, not proof that the capsule is failing. The WHO’s 2024 obesity resource supports dietary approaches that reduce energy density, and lower-fat meal choices also reduce this unwanted effect. Persistent diarrhoea, severe pain, or dehydration needs medical assessment. Contact a clinician if these symptoms continue despite lower-fat meals.
Yes. Vitamins A, D, E, and K are fat-soluble, meaning dietary fat helps the body absorb them. Orlistat may reduce uptake of these vitamins, which is why a multivitamin is usually separated from the capsule dose. The U.S. National Library of Medicine updated its orlistat medicine guidance in 2024 to include vitamin supplementation and dose separation. Vitamin K changes are more relevant for people using warfarin because INR control can be affected.
The combination needs timing and monitoring because orlistat may reduce levothyroxine absorption. Separate the medicines by at least four hours. The FDA’s 2024 orlistat prescribing information identifies hypothyroidism and altered thyroid control as clinically relevant concerns with this combination. Symptoms such as new fatigue, constipation, feeling cold, or changes in heart rate warrant thyroid-function review.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
I lost weight gradually after I started planning lunch instead of grabbing fried food. The first weekend was awkward because I had a rich brunch and needed the toilet quickly. Once I changed that meal, the issue settled.
I expected less hunger, but that was not what I felt. The helpful part was that it made me more aware of fat in sauces and snacks. I added a bedtime multivitamin and found the routine easy.
The bowel effects were stronger than I expected during the first ten days. I had not realised how much oil was in some home-cooked dishes. It worked better after I measured cooking oil rather than pouring freely.
My weight trend moved in the right direction, though it was slower than I wanted. I found it useful for keeping my meals structured, but I skipped doses with fruit-only breakfasts and did not try to compensate later.
